Alessandro Rossi

Dr. Alessandro Rossi

University of Naples Federico II, Naples, Campania, Italy
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMariangela Succoio
Mariangela Succoio
RSRosa Sacchettini
Rosa Sacchettini
ARAlessandro Rossi
Alessandro Rossi
GPGiancarlo Parenti
Giancarlo Parenti
Margherita RuoppoloMargherita Ruoppolo
Margherita Ruoppolo
Galactosemia is an inborn disorder of carbohydrate metabolism characterized by the inability to metabolize galactose, a sugar contained in milk (the main source of nourishment for infants), and convert it into glucose, the sugar used by the body as the primary source of energy. Galactosemia is an autosomal recessive genetic disease that can be diagnosed at birth, even in the absence of symptoms, with newborn screening by assessing the level of galactose and the GALT enzyme activity, as GALT defect constitutes the most frequent cause of galactosemia. Currently, galactosemia cannot be cured, but only treated by means of a diet with a reduced content of galactose and lactose. Although the diet is able to reverse the neonatal clinical picture, it does not prevent the development of long-term complications. This review provides an overview of galactose metabolism, molecular genetics, newborn screening and therapy of galactosemia. Novel treatments for galactosemia currently being investigated in (pre)clinical studies and potentially able to prevent long-term complications are also presented.

27 October 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
TDTerry G.J. Derks
Terry G.J. Derks
DRDavid F. Rodriguez-Buritica
David F. Rodriguez-Buritica
AAAyesha Ahmad
Ayesha Ahmad
FBFoekje de Boer
Foekje de Boer
María L. CouceMaría L. Couce
María L. Couce
JMJohn Mitchell
John Mitchell
Glycogen storage disease type Ia (GSDIa) is caused by defective glucose-6-phosphatase, a key enzyme in carbohydrate metabolism. Affected individuals cannot release glucose during fasting and accumulate excess glycogen and fat in the liver and kidney, putting them at risk of severe hypoglycaemia and secondary metabolic perturbations. Good glycaemic/metabolic control through strict dietary treatment and regular doses of uncooked cornstarch (UCCS) is essential for preventing hypoglycaemia and long-term complications. Dietary treatment has improved the prognosis for patients with GSDIa; however, the disease itself, its management and monitoring have significant physical, psychological and psychosocial burden on individuals and parents/caregivers. Hypoglycaemia risk persists if a single dose of UCCS is delayed/missed or in cases of gastrointestinal intolerance. UCCS therapy is imprecise, does not treat the cause of disease, may trigger secondary metabolic manifestations and may not prevent long-term complications. We review the importance of and challenges associated with achieving good glycaemic/metabolic control in individuals with GSDIa and how this should be balanced with age-specific psychosocial development towards independence, management of anxiety and preservation of quality of life (QoL). The unmet need for treatment strategies that address the cause of disease, restore glucose homeostasis, reduce the risk of hypoglycaemia/secondary metabolic perturbations and improve QoL is also discussed.

2 July 2021 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
ARAlessandro Rossi
Alessandro Rossi
EMErasmo Miele
Erasmo Miele
SFSimona Fecarotta
Simona Fecarotta
MVMaria Veiga-Da-Cunha
Maria Veiga-Da-Cunha
MMMassimo Martinelli
Massimo Martinelli
GPGiancarlo Parenti
Giancarlo Parenti
Background: Besides major clinical/biochemical features, neutropenia and inflammatory bowel disease (IBD) constitute common complications of Glycogen storage disease type Ib (GSD Ib). However, their management is still challenging. Although previous reports have shown benefit of empagliflozin administration on neutropenia, no follow-up data on bowel (macro/microscopic) morphology are available. We herein present for the first time longitudinal assessment of bowel morphology in a GSD Ib child suffering from Crohn disease-like enterocolitis treated with empagliflozin. Case presentation: A 14-year-old boy with GSD Ib and severe IBD was (off-label) treated with empagliflozin (20 mg/day) after informed oral and written consent was obtained from the patient’s parents. No adverse events were noted. Clinical symptoms and stool frequency improved within the first week of treatment. Pediatric Crohn disease activity index (PCDAI) normalised within the first month of treatment. Abdomen magnetic resonance imaging (MRI) performed 3 months after treatment initiation showed dramatic decrease in disease activity and length. Similar findings were reported on histology at 5.5 months. At 7.5 months hemoglobin levels normalised and fecal calprotectin almost normalised. Improved neutrophil count, metabolic control and quality of life were also noted. G-CSF dose was decreased by 33% and the patient was partly weaned from tube feeding. Conclusions: This is the first report presenting extensive gastrointestinal morphology follow-up in a GSD Ib patient receiving empagliflozin. The present case suggests that empagliflozin can be safe and effective in inducing IBD remission in GSD Ib patients and can even postpone surgery. Future studies are required to confirm its effect over time and assess its benefit in various disease stages. The development of an international collaborating networks for systematic data collection is worthy.

12 February 2018 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
ARAlessandro Rossi
Alessandro Rossi
Margherita RuoppoloMargherita Ruoppolo
Margherita Ruoppolo
Pietro FormisanoPietro Formisano
Pietro Formisano
GVGuglielmo Rosario Domenico VILLANI
Guglielmo Rosario Domenico VILLANI
LALucia Albano
Lucia Albano
DMDaniela Melis
Daniela Melis


16 February 2020 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
ARAlessandro Rossi
Alessandro Rossi
IHIrene J. Hoogeveen
Irene J. Hoogeveen
VBVanessa B. Bastek
Vanessa B. Bastek
FBFoekje de Boer
Foekje de Boer
CMChiara Montanari
Chiara Montanari
TDTerry G.J. Derks
Terry G.J. Derks
Summary: A potential role of dietary lipids in the management of hepatic glycogen storage diseases (GSDs) has been proposed, but no consensus on management guidelines exists. The aim of this study was to describe current experiences with dietary lipid manipulations in hepatic GSD patients. An international study was set up to identify published and unpublished cases describing hepatic GSD patients with a dietary lipid manipulation. A literature search was performed according to the Cochrane Collaboration methodology through PubMed and EMBASE (up to December 2018). All delegates who attended the dietetics session at the IGSD2017, Groningen were invited to share unpublished cases. Due to multiple biases, only data on GSDIII were presented. A total of 28 cases with GSDIII and a dietary lipid manipulation were identified. Main indications were cardiomyopathy and/or myopathy. A high fat diet was the most common dietary lipid manipulation. A decline in creatine kinase concentrations (n = 19, P < .001) and a decrease in cardiac hypertrophy in paediatric GSDIIIa patients (n = 7, P < .01) were observed after the introduction with a high fat diet. This study presents an international cohort of GSDIII patients with different dietary lipid manipulations. High fat diet may be beneficial in paediatric GSDIIIa patients with cardiac hypertrophy, but careful long‐term monitoring for potential complications is warranted, such as growth restriction, liver inflammation, and hepatocellular carcinoma development.